title: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence.
abstract: OBJECTIVE
  To review epidemiologic studies on the association between homocyst(e)ine level and risk for cardiovascular disease and the potential benefits of homocysteine-decreasing therapies.
  
  
  METHODS
  Computerized and manual searches of the literature on total homocysteine levels and cardiovascular disease.
  
  
  METHODS
  Prospective studies and major retrospective epidemiologic studies evaluating the association between homocyst(e)ine levels and cardiovascular disease and the association between blood levels or dietary intake of folate, vitamin B6, and vitamin B12 and cardiovascular disease.
  
  
  METHODS
  Relevant data on patient population, plasma homocyst(e)ine levels, duration of follow-up, and main results were extracted from studies that met the inclusion criteria.
  
  
  RESULTS
  The designs and results of studies included in this review are summarized. A formal meta-analysis was not performed because the studies were heterogeneous in method and design.
  
  
  CONCLUSIONS
  Results of epidemiologic studies suggest that moderately elevated plasma or serum homocyst(e)ine levels are prevalent in the general population and are associated with an increased risk for cardiovascular disease, independent of classic cardiovascular risk factors. Simple, inexpensive, nontoxic therapy with folic acid, vitamin B6, and vitamin B12 reduces plasma homocyst(e)ine levels. Although the association between homocyst(e)ine levels and cardiovascular disease is generally strong and biologically plausible, the data from the prospective studies are less consistent. In addition, epidemiologic observations of an association between hyperhomocyst(e)inemia and cardiovascular risk do not prove the existence of a causal relation. Therefore, the effectiveness of folate, vitamin B6, and vitamin B12 in reducing cardiovascular morbidity and mortality requires rigorous testing in randomized clinical trials. Several such trials are under way; their results may greatly affect cardiovascular morbidity and mortality, given the simplicity and low cost of vitamin therapy.
authors.affiliation: Preventive Cardiology and Therapeutics Program, McMaster University, Hamilton, Ontario, Canada.
authors.forename: J W
authors.initials: JW
authors.lastname: Eikelboom
authors.forename: E
authors.initials: E
authors.lastname: Lonn
authors.forename: J
authors.initials: J
authors.lastname: Genest
authors.forename: G
authors.initials: G
authors.lastname: Hankey
authors.forename: S
authors.initials: S
authors.lastname: Yusuf
mesh_terms: D001161:Arteriosclerosis / Q000097:blood / Q000453:epidemiology; D002318:Cardiovascular Diseases / Q000097:blood / Q000453:epidemiology*; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000503:physiopathology; D012307:Risk Factors; D014803:Vitamin B Complex / Q000097:blood*
chemical_list: D006710:Homocysteine; D014803:Vitamin B Complex